Migration notice:
On August 9th, 2025, Finsight.com market data will be renamed and migrated to CreditFlow, a more intuitive, comprehensive and accessible market data platform for all credit products.
Contact us
for more information.
Market Data
Pricing
Solutions
Log In
Market Overview
Financials
Asset Management & Custody Banks
Parent Companies
Taizhou Huaxin Pharmaceutical Investment Co Ltd
Huaxin Pharmaceutical Hong Kong Co Ltd
2017-1
Huaxin Pharmaceutical Hong Kong Co Ltd (HAXNP) 2017-1
C/P
Sector
Status
Deal Name
Parent
Leads
Region
Date
HYC
FNCL
PRCD
HAXNP 2017-1 (USD 120m)
Taizhou Huaxin Pharmaceutical Investment Co Ltd
HAT
APAC
Oct 17, 2017
CCY
SIZE (M)
TNR
MTY
RNK
MO
SP
FI
TYPE
BNCH
IPT
GDNC
SPRD
CPN
NIC
PRICE
OQX
833.000
3
Mar-07
Dw. Laomvwwmt
-
-
-
Twmwl
-
-
-
-
4.50%
-
161.00000
Tranche Comments
1 zz: Registration: Hko K Wfqg; Comments: OWT120y 1 bf 4.50% Ypj. ynf unyre Lrn W mnzb. Qvqqmnn/ Wbvnnnu Oyqv/ Tqeqmfb Wreufqqqry . 4.50%. Fqprj;
Guarantor(s)
Ggfyabp Mpgqfk Aagqzgqapyfqgo Rkmasyzaky Kb., Cyp.
Commentary
Upgrade Plan
Deal Flow
Upgrade Plan
Missing something? Tell us.